Frontiers in genetics · 2025
Biological characteristics and prognosis of acute myeloid leukemia in elderly patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Zhe, Ding Lina, Yu Jieni, Jin Jing, Zhang Zhijian, Fu Jiaping, Hong Pan, Fu Leihua
Аннотация
BACKGROUND: Our study aimed to investigate the effects of chromosomal aberrations and genetic mutations of elderly individuals diagnosed with AML and determine its prognostic significance.
METHODS: We retrospectively collected data over nearly 7 years from our hospital, encompassing 90 cases of elderly AML patients. Baseline information of patients was gathered and followed up, and statistical analysis was conducted using SPSS 25.0.
RESULTS: Among the 90 elderly non-M3 AML patients, 56 (62.2%) exhibited multiple gene mutations, with 9 (10%) patients displaying five or more gene mutations. The incidence of NPM1 mutation was significantly higher in patients with normal karyotypes compared to those with abnormal karyotypes (P = 0.001). Patients with FLT3, ASXL1, or TP53 mutations displayed lower rates of CR compared to wild-type counterparts. Kaplan-Meier analysis revealed that TET2 mutation (P = 0.0474), FLT3-ITD mutation (P = 0.0364), TP53 mutation (P = 0.0031), and 17p abnormality (P = 0.00285) were predictive of shorter OS. TP53 mutations (P = 0.0440), 17p abnormalities (P = 0.0272), 7q abnormalities (P = 0.0174), and complex karyotypes (P = 0.0447) were associated with shorter RFS.
CONCLUSION: Our findings suggest that elderly AML patients exhibit distinctive genetic profiles, and favorable prognosis genes do not seem to apply to elderly AML patients.
METHODS: We retrospectively collected data over nearly 7 years from our hospital, encompassing 90 cases of elderly AML patients. Baseline information of patients was gathered and followed up, and statistical analysis was conducted using SPSS 25.0.
RESULTS: Among the 90 elderly non-M3 AML patients, 56 (62.2%) exhibited multiple gene mutations, with 9 (10%) patients displaying five or more gene mutations. The incidence of NPM1 mutation was significantly higher in patients with normal karyotypes compared to those with abnormal karyotypes (P = 0.001). Patients with FLT3, ASXL1, or TP53 mutations displayed lower rates of CR compared to wild-type counterparts. Kaplan-Meier analysis revealed that TET2 mutation (P = 0.0474), FLT3-ITD mutation (P = 0.0364), TP53 mutation (P = 0.0031), and 17p abnormality (P = 0.00285) were predictive of shorter OS. TP53 mutations (P = 0.0440), 17p abnormalities (P = 0.0272), 7q abnormalities (P = 0.0174), and complex karyotypes (P = 0.0447) were associated with shorter RFS.
CONCLUSION: Our findings suggest that elderly AML patients exhibit distinctive genetic profiles, and favorable prognosis genes do not seem to apply to elderly AML patients.